Natera Reports Largest Lung Cancer MRD Study for Signatera
AUSTIN, Texas — September 18, 2026 Natera announced new data from the IASLC 2026 World Conference on Lung Cancer...
overall survival
Advertisement
Summit Therapeutics Reports Ivonescimab Survival Data at WCLC
Los Angeles, California, September 15, 2026 Summit Therapeutics has announced positive overall survival results from the Phase 3 HARMONi-2...
J&J’s RYBREVANT Shows Longest OS in EGFR Lung Cancer
Raritan, New Jersey, U.S., September 14, 2026 Johnson & Johnson announced new overall survival data from the Phase III...
AstraZeneca’s Tagrisso Delivers 8-Year Survival in Lung Cancer
Wilmington, Delaware, U.S., September 14, 2026 AstraZeneca announced updated results from the Phase III ADAURA trial, showing sustained long-term...
Amgen and AstraZeneca’s IMDELLTRA-IMFINZI Improves SCLC Survival
Thousand Oaks, California, USA, September 8, 2026 Amgen and AstraZeneca have announced positive results from the Phase 3 DeLLphi-305...
Advertisements
Akeso Reports Ivonescimab OS Benefit in HARMONi-2
Hong Kong, September 3, 2026 Akeso, Inc. has announced that a prespecified interim analysis of overall survival (OS) in...
Kazia Paxalisib Shows Potential in Resistant Colorectal Cancer
Sydney, Australia, September 1, 2026 Kazia Therapeutics Limited has reported new preclinical and translational findings suggesting that its investigational...
HUTCHMED Reports Phase III Lung Cancer Trial Success
Hong Kong, Shanghai, China, and Florham Park, New Jersey, August 31, 2026 HUTCHMED (China) Limited has announced positive high-level...
Can-Fite Reports Longer Overall Survival in Phase III Liver Cancer Study
RAMAT GAN, Israel, September 2, 2026 Can-Fite BioPharma Ltd. reported that blinded overall survival observed across the entire patient...
Jazz Reports Survival Benefit for Ziihera in GEA
Dublin, Ireland, August 31, 2026 Jazz Pharmaceuticals plc announced positive topline results from the Phase 3 HERIZON-GEA-01 clinical trial,...
Advertisement
